Renalys Pharma secures ¥6.0 billion in Series A financing, co-led by Catalys Pacific and SR One, to advance its Phase III clinical trial for sparsentan, targeting IgA nephropathy in Japan and Asia.
Information on the Target
Renalys Pharma, Inc. is a late-stage clinical biopharmaceutical company based in Japan, focused on developing innovative therapies for managing renal diseases. Recently, the company successfully completed a ¥6.0 billion Series A financing round, co-led by Catalys Pacific and SR One, to advance its Phase III clinical trial for sparsentan, a treatment specifically targeting IgA nephropathy. Through a licensing agreement with Travere Therapeutics, Inc., Renalys Pharma has secured rights to administer this promising therapeutic option in Japan and other Asian markets.
IgA nephropathy represents a significant burden in Japan and throughout Asia, highlighting the pressing need for effective treatment solutions. With the upcoming open-label registrational study set to commence in Q2 2024, Renalys Pharma aims to offer critical treatment options for patients suffering from this prevalent kidney disease by aiming for regulatory approval in the near future.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Japan
The biopharmaceutical industry in Japan has seen substantial growth due to increasing healthcare demands and advancements in medical technology. Japan's aging population coupled with rising incidences of chronic diseas
Similar Deals
Catalys Pacific and SR One
invested in
Renalys Pharma, Inc.
in 2024
in a Series A deal
Disclosed details
Transaction Size: $40M